C1 inhibitor muteins and uses thereof

Details C1 inhibitor muteins and uses thereof C1 inhibitor muteins and uses thereof

1991-09-05

1997-04-22

Walsh, Stephen G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

530380, 530395, A61K 3857, C07K 1481

Patent

active

056229305

ABSTRACT:
Compositions consisting of C1 inhibitor muteins having biological activity similar to C1 inhibitor, but with enhanced resistance to proteolytic cleavage thus rendering such muteins suitable as anti inflammatory agents, preferably for the treatment or prevention of sepsis.

REFERENCES:
patent: 4915945 (1990-04-01), Pelzer et al.
patent: 5030578 (1991-07-01), Pilatte et al.
patent: 5271931 (1993-12-01), Lotz et al.
Hack, et al. "Elevated Plasma Levels of the Anaphylatoxins C3a and C4a are Associated with a Fatal Outcome in Sepsis," The American Journal of Medicine, 86:20-26 (Jan. 1989).
Schnebli, et al. "Elgin c, a Pharmacologically Active Elastase Inhibitor," Eur. J. Respir Dis. 66, Suppl. 139, 66-70 (1985).
Bock et al. Biochemistry 25(15):4292-4301 (1986).
Eldering et al. J. Biol. Chem. 263(24):11776-79 (1988).
Skrive et al. J. Biol. Chem. 264(6)3066-71 (1989).
Schapira et al. J. Clin. Invest 80:582-585 (1987).
Eldering, E., et al., Sep. 10-15, 1989, Complement Inflammation, 6(5), Abstract No. 68, p. 333.
Eldering, E., et al. Sep. 10-15, 1989, Complement Inflammation, 6(5), Abstract No. 69, p. 333.

Affiliated with

Also associated with

Rating

C1 inhibitor muteins and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C1 inhibitor muteins and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C1 inhibitor muteins and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-341571